These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35900373)

  • 1. MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH.
    Wang Y; Shen QL; Xin Q; Sun B; Zhang S; Fang QH; Shi YX; Niu WY; Lin JN; Li CJ
    J Mol Endocrinol; 2022 Oct; 69(3):415-430. PubMed ID: 35900373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus.
    Bose SK; Kim H; Meyer K; Wolins N; Davidson NO; Ray R
    J Virol; 2014 Apr; 88(8):4195-203. PubMed ID: 24478438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
    Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
    Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease.
    Tang C; Deng X; Qu J; Miao Y; Tian L; Zhang M; Li X; Sun B; Chen L
    Drug Des Devel Ther; 2023; 17():1503-1514. PubMed ID: 37223723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice.
    Herrema H; Derks TG; van Dijk TH; Bloks VW; Gerding A; Havinga R; Tietge UJ; Müller M; Smit GP; Kuipers F; Reijngoud DJ
    Hepatology; 2008 Jun; 47(6):1894-904. PubMed ID: 18459129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis
    Fernández-Ramos D; Lopitz-Otsoa F; Delacruz-Villar L; Bilbao J; Pagano M; Mosca L; Bizkarguenaga M; Serrano-Macia M; Azkargorta M; Iruarrizaga-Lejarreta M; Sot J; Tsvirkun D; van Liempd SM; Goni FM; Alonso C; Martínez-Chantar ML; Elortza F; Hayardeny L; Lu SC; Mato JM
    World J Gastroenterol; 2020 Sep; 26(34):5101-5117. PubMed ID: 32982112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency.
    Karunanidhi A; Basu S; Zhao XJ; D'Annibale O; Van't Land C; Vockley J; Mohsen AW
    Mol Genet Metab; 2023 Nov; 140(3):107689. PubMed ID: 37660571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Wan J; Zhang Y; Yang D; Liang Y; Yang L; Hu S; Liu Z; Fang Q; Tian S; Ding Y
    Hepatology; 2021 Dec; 74(6):3074-3090. PubMed ID: 34297426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
    Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
    BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
    J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice.
    Tolwani RJ; Hamm DA; Tian L; Sharer JD; Vockley J; Rinaldo P; Matern D; Schoeb TR; Wood PA
    PLoS Genet; 2005 Aug; 1(2):e23. PubMed ID: 16121256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L; Fang K; Dan X; Gu M
    Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dietary fat contributes to dysregulation of the LKB1/AMPK pathway and increased damage in a mouse model of early-stage ethanol-mediated steatosis.
    Shearn CT; Smathers RL; Jiang H; Orlicky DJ; Maclean KN; Petersen DR
    J Nutr Biochem; 2013 Aug; 24(8):1436-45. PubMed ID: 23465594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice.
    Hu M; Zhang D; Xu H; Zhang Y; Shi H; Huang X; Wang X; Wu Y; Qi Z
    Hepatology; 2021 Dec; 74(6):3056-3073. PubMed ID: 34292604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
    Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW
    Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.